Article
Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
Oral oncology - 1 Jan 2017
Swick Adam D, Stein Andrew P, McCulloch Timothy M, Hartig Gregory K, Ong Irene M, Sampene Emmanuel, Prabakaran Prashanth J, Liu Cheng Z, Kimple Randall J
Abstract excerpt
BACKGROUND: Patient derived xenografts (PDXs) represent an essential tool in oncologic research, and we sought to further expand our repertoire of head and neck squamous cell carcinoma (HNSCC) while determining potential boundaries for this system. METHODS: We consented new patients for PDX development and determined if a 24-h time delay from tumor excision to xenograft implantation affected PDX establishment. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
